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OBJECTIVE—To understand why atherogenic risk differs more
between diabetic and nondiabetic women than between diabetic
and nondiabetic men.
RESEARCH DESIGN AND METHODS AND RESULTS—
Measures of cardiovascular risk, body composition, and serum
hormones from the baseline examinations of the Insulin Resis-
tance Atherosclerosis Study on 524 nondiabetic women, 258
diabetic women, 421 nondiabetic men, and 220 diabetic men
were compared to detect greater adverse differences in women
than in men. Systolic blood pressure; apolipoprotein B (apoB);
total cholesterol; apoB–to–apoA-I ratio; non-HDL cholesterol;
LDL particle count, small LDL, and intermediate-density lipopro-
tein by nuclear magnetic resonance; and C-reactive protein
exhibited signiﬁcant diabetes-sex interaction (P  0.05). ApoB
exhibited the most signiﬁcant interaction (P  0.0005). Age- and
ethnicity-adjusted apoB means were lower in nondiabetic
women than nondiabetic men (102.4 vs. 106.8 mg/dl, P  0.05)
but higher in diabetes (115.7 vs. 110.2 mg/dl, P  0.01). Plotted
against BMI, waist circumference was 6% higher and hip circum-
ference 10% lower in diabetic than nondiabetic women (both P 
0.05), whereas the circumference measures did not differ con-
spicuously between diabetic and nondiabetic men.
CONCLUSIONS—In diabetic women, an elevated level of
atherogenic particles, as manifested by apoB and LDL particle
count, which may result from abdominal adiposity, represents a
major treatable cardiovascular risk factor. Diabetes 57:3289–
3296, 2008
A
lthough the gap narrows after menopause, gen-
erally the risk of vascular disease is greater in
men than in women. In diabetes, by contrast,
risk is similar in men and women (1). The
equalization of risk is due to the disproportionately greater
increase in risk in women who develop diabetes compared
with men who develop diabetes (2–4). Identifying the
reasons for this alarming increase in vascular disease in
diabetic women is critical. Previous work has established
that both sexes have higher plasma triglycerides and lower
HDL cholesterol levels in diabetes (5) and that these
differences are more pronounced between nondiabetic
and diabetic women than between nondiabetic and dia-
betic men (6–8). However, the differences, if any, in LDL
cholesterol are much less pronounced and range from
slight decreases to slight increases in diabetes (5). Thus,
the differences in the conventional lipid proﬁle appear
inadequate to explain the differences in clinical risk that
have been recorded (2,9).
Because the evidence that apolipoprotein B (apoB) is
superior to LDL cholesterol as a marker of atherogenic
risk is sufﬁciently clear (10–14), the American Diabetes
Association and the American College of Cardiology have
issued a joint consensus statement (15) that apoB should
be the ﬁnal test of the adequacy of LDL-lowering therapy
(15,16). Nevertheless, only limited information is avail-
able on apoB in diabetic subjects compared with non-
diabetic subjects. Two studies have noted that apoB was
signiﬁcantly higher in diabetic compared with nondia-
betic women with no signiﬁcant differences between
diabetic and nondiabetic men (17,18). No explanation
was offered for this sex difference. Equally important,
no mechanism has been suggested that might explain
why diabetes in women induces more cardiovascular
risk than in men.
The purpose of this study, therefore, was to characterize
the lipoprotein proﬁle in greater detail in larger groups of
diabetic and nondiabetic men and women than previously
examined. We also examined whether the data suggest
possible mechanisms that could account for the greater
differences in atherogenic risk proﬁle between diabetic
and nondiabetic women than between diabetic and nondi-
abetic men.
RESEARCH DESIGN AND METHODS
The Insulin Resistance Atherosclerosis Study (IRAS) is a multicenter, epide-
miological study designed to explore relationships between insulin resistance,
cardiovascular risk factors, and disease across different ethnic groups and
varying states of glucose tolerance. The IRAS protocol was approved by
participating local institutional review committees, and all subjects gave
informed consent. Study participants were recruited to obtain approximately
equal numbers with diabetes, impaired glucose tolerance, and normal glucose
tolerance from each ethnic group and center. A total of 1,624 individuals
participated in IRAS baseline examinations from October 1992 to April 1994.
This report includes data on 1,423 subjects after excluding 128 subjects who
lacked nuclear magnetic resonance (NMR) lipid measurements, 63 who did
not have an intravenous glucose tolerance test for insulin sensitivity assess-
ment, and 10 without an apoB assay. Serum sex hormone-binding globulin
(SHBG), estradiol, and testosterone concentrations were measured using
standardized assays from Diagnostic Products (Siemens). Intra- and interas-
say coefﬁcients of variation were, respectively, 5.3 and 8.5% for SHBG,
7.0 and 8.1% for estradiol, and 10.0 (values 100 ng/dl) and 7.3% for
testosterone. Descriptions of the other measures used in this analysis have
been published (19,20).
Statistical analyses. ANCOVA with age, ethnicity (non-Hispanic white,
African American, or Hispanic), diabetes, sex, and diabetes-sex interaction
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tions. Cardiovascular risk factors, estimates of body composition, and serum
hormones known to be associated with sex, diabetes, and/or cardiovascular
risk were included. We then added the risk factor with the most signiﬁcant
interaction to the ANCOVA model for each other risk factor that exhibited
signiﬁcant interaction. Finally, we examined the distributions and conducted
ad hoc correlation/regression analyses, including the measures thus selected.
Generalized estimating equations with waist and hip circumferences counted
in two observations per subject were used to test the difference in slopes
versus BMI.
Statistical calculations were performed in SAS version 9.1 (Cary, NC).
Log-transformed values were used in analyses of continuous variables which
appeared to be more normally distributed with transformation than without.
In light of the exploratory nature of these ancillary analyses, P values 0.05
were considered statistically signiﬁcant warranting investigation in other
studies.
RESULTS
Table 1 details descriptive statistics for the study subjects.
All groups were similar with respect to ethnic composi-
tion. Also, the proportion of those with impaired glucose
regulation did not differ between nondiabetic men and
women. As anticipated, age, fasting glucose, 2-h glucose,
fasting insulin, hyperlipidemia treatment rates, and hyper-
tension treatment rates were signiﬁcantly different in both
diabetic groups compared with nondiabetic ones with the
exception of hyperlipidemia treatment in men (9% in both
male groups). Among nondiabetic subjects, mean 2-h
glucose was higher in women than in men (by t test, P 
0.023), whereas the percentage of subjects with impaired
glucose regulation was higher in men than in women (by

2 test, P  0.021), and the percentage on hyperlipidemia
treatment was also higher in men (9 vs. 5%, P  0.014).
There were no signiﬁcant differences in Table 1 between
diabetic women and diabetic men.
Cardiovascular risk factors. With regard to cardiovas-
cular risk factors (Table 2), systolic blood pressure and
C-reactive protein (CRP) were higher in both diabetic men
and diabetic women compared with their nondiabetic
counterparts. Both of these differences were more than
two times greater in women than in men and operate to
increase risk in diabetic women.
The differences in atherogenic lipoprotein proﬁle were
much more striking between diabetic women and nondia-
betic women than between diabetic men and nondiabetic
men. All four markers of the concentration of atherogenic
lipoproteins—apoB, LDL cholesterol, non-HDL choles-
terol, and LDL particle count—were signiﬁcantly higher in
diabetic women compared with nondiabetic women. ApoB
and non-HDL cholesterol were not signiﬁcantly different
between diabetic and nondiabetic men; LDL cholesterol
was actually greater in nondiabetic men compared with
diabetic men, whereas LDL particle count was higher in
diabetic men compared with nondiabetic men. Nondia-
betic men had higher apoB levels than nondiabetic
women. However, diabetic women had higher apoB than
diabetic men.
These differences in the four major atherogenic lipopro-
tein indexes are illustrated in Fig. 1. For men, there were
only minor differences in the distribution of values for all
four indexes between those with and without diabetes.
For women, although the average value for LDL choles-
terol in diabetic women was 5.6 mg/dl greater than in
nondiabetic women (P  0.05), there was no signiﬁcant
difference in the distribution of values of LDL cholesterol
between diabetic and nondiabetic women. Moreover,
there was no signiﬁcant increase in the proportion of
women with an elevated LDL cholesterol. By contrast,
substantial differences were evident for apoB. Not only
was the mean difference between the two groups of
women greater (13.3 mg/dl, P  0.001) than for LDL
cholesterol, the distribution of values in diabetic women
was shifted toward higher values with nearly a doubling of
the proportion with a markedly elevated level (41 vs. 23%,
P  0.0001). All of these ﬁndings were conﬁrmed by the
differences observed in LDL particle count. Of importance,
the differences in non-HDL cholesterol were intermediate
between LDL cholesterol and apoB.
Plasma triglycerides were signiﬁcantly higher in both
diabetic groups than nondiabetic groups, but no signiﬁcant
sex-diabetes interaction was observed. However, VLDL
and intermediate-density lipoprotein (IDL) particle num-
ber were higher only in diabetic women compared with
nondiabetic women. LDL particle number was higher in
diabetic men compared with their nondiabetic counter-
parts, but the differences were more marked in women.
LDL particle number was similar in both diabetic men and
women. As expected from the plasma triglycerides, LDL
size was lower in both diabetic groups. Equal percentages
of nondiabetic men and women had hypertriglyceridemia
(hyperTg)/hyperapobetalipoproteinemia (hyperapoB) (15.8
and 15.7%, respectively). Of the diabetic groups, 24.1% of
men vs. 32.8% of women had hyperTg/hyperapoB (P 
0.036). Fasting plasma free fatty acids (FFAs) were highest
in diabetic women. HDL cholesterol and apoA-I were
signiﬁcantly lower in diabetic women than in nondiabetic
women. The difference between the apoB–to–apoA-I ratio
was signiﬁcantly greater between diabetic and nondiabetic
women than between the comparable groups of men (P 
0.0045), whereas these same differences in total-to-HDL
cholesterol ratio were marginally nonsigniﬁcant (P 
0.063) in this data.
TABLE 1
Descriptive statistics of the study sample
Nondiabetic
women
Diabetic
women*
Nondiabetic
men
Diabetic
men*
n 524 258 421 220
Age (years) 55  85 7  85 5  95 7  8
Hispanic/black/non-Hispanic white (%) 37/27/36 32/34/34 44/23/33 38/33/29
Impaired glucose regulation (%)† 48 — 56‡ —
Fasting glucose (mg/dl) 96  11 168  58 100  9 172  58
2-h Glucose (mg/dl) 126  33 309  90 121  33‡ 302  90
On medication for hyperlipidemia (%) 5 10 9‡ 9
On medication for hypertension 23 40 22 35
Data are means  SD or percent. *Diabetes diagnosed by 1999 World Health Organization criteria: fasting glucose, 126 mg/dl; 2-h glucose,
200 mg/dl or on hypoglycemic medication. †Fasting glucose 100 mg/dl or 2-h glucose 140 mg/dl. ‡P  0.05 vs. nondiabetic women.
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DIABETES, VOL. 57, DECEMBER 2008 3291Finally, apoB appeared to be the key measure charac-
terizing the cardiovascular risk factor interactions. As
shown in Table 3, further adjustment for apoB abolished
the signiﬁcance of the sex-diabetes interaction of each of
the other cardiovascular risk measures. Of note in this
regard is that adjustment for apoB attenuated the interac-
tion of systolic blood pressure from a marginally signiﬁ-
cant (P  0.037) 3.76-mmHg interaction effect (difference
in the differences) in Table 2 to a marginally nonsigniﬁcant
(P  0.092) 3.04-mmHg interaction effect in Table 3. Also,
the interaction effect of LDL cholesterol changes from a
highly signiﬁcant 13.9 mg/dl (P  0.0006) to a marginally
nonsigniﬁcant 5.7 mg/dl (P  0.076). Adjusting for apoB
attenuated the magnitude of the other interactions by at
least 48%, and all were more than marginally nonsigniﬁ-
cant (P  0.10).
Body composition. Table 2 lists the principal results for
all of the major groups. All four measures—waist circum-
ference, hip circumference, waist-to-hip ratio (WHR), and
BMI—were signiﬁcantly higher in both diabetic groups
compared with their nondiabetic counterparts. Both dia-
betic groups were more obese than the nondiabetic ones,
and the increase in adipose tissue mass was generalized
but more accentuated in the abdominal region. It is
noteworthy that the difference in the WHR and waist
circumference in diabetic compared with nondiabetic
women was signiﬁcantly greater than the difference be-
tween diabetic and nondiabetic men. Also, waist circum-
ference for diabetic women was signiﬁcantly greater than
for nondiabetic men (P  0.001).
Figure 2 contrasts the differences in body composition
expressed as a ratio of waist or hip circumference at the
FIG. 1. Histograms of apoB (A), LDL cholesterol (B), non-HDL cholesterol (C), and LDL particle count (D) by sex and diabetes status. 
2
comparisons of the proportions above selected risk thresholds among diabetic versus nondiabetic subjects were as follows. A: Of diabetic women,
41% had apoB >120 mg/dl vs. 23% of nondiabetic women, P < 0.0001; 30% of diabetic vs. 26% of nondiabetic men, P  0.22. B: Of diabetic women,
31% had LDL cholesterol >160 mg/dl vs. 27% of nondiabetic women, P  0.19; 24% of diabetic vs. 29% of nondiabetic men, P  0.14. C: Of diabetic
women, 32% had non-HDL cholesterol >190 mg/dl vs. 23% of nondiabetic women, P  0.003; 29% of diabetic vs. 24% of diabetic men, P  0.16.
D: Of diabetic women, 20% had LDL particle count >1,617 nmol/l vs. 10% of nondiabetic women, P  0.0002; 12% of diabetic vs. 10% of
nondiabetic men, P  0.28.
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Fig. 2A and B demonstrate that as BMI increased, upper
body tissue mass (as measured by waist circumference)
increased more than lower body mass (hip circumference)
in all groups (P  0.001). The trend was more pronounced
in women than in men (P  0.001). In men (Fig. 2C), there
was little difference in the slopes and intercepts of either
waist or hip circumference between the two groups at any
given BMI. By contrast in women (Fig. 2D) at any given
BMI, waist circumference was 6% greater (P  0.001) in
diabetic compared with nondiabetic women. On the other
hand, hip circumference was 10% lower at any given BMI
in diabetic compared with nondiabetic women. Thus,
comparing diabetic with nondiabetic subjects, expansion
of lower body adipose tissue mass was considerably
more constrained in women, whereas expansion of
upper body abdominal tissue mass was considerably
more pronounced.
Serum hormones. With regard to serum hormones (Table
2), as expected, serum fasting insulin was higher in both
sexes in diabetic subjects compared with nondiabetic
subjects, total testosterone levels were 20 times higher
in men than women, whereas estradiol levels in women
were double that in men. SHBG levels were markedly
lower in diabetic compared with nondiabetic women
with a smaller, although still signiﬁcant, difference
noted between the two groups of men. As a result,
diabetic women SHBG levels did not differ signiﬁcantly
from nondiabetic men. Diabetic men had signiﬁcantly
lower levels of testosterone than nondiabetic men while
diabetic women had signiﬁcantly higher testosterone
than nondiabetic women.
Although the diabetes-sex interaction of fasting insulin
was not signiﬁcant, there was a signiﬁcant sex interaction
(P  0.0001) in the association between waist circumfer-
ence and insulin (Fig. 3): The difference in waist between
men and women in the highest quintile of insulin was less
than one-half the same difference in the lowest insulin
quintile. When SHBG was added to this association with
waist circumference, sex-SHBG interaction was nonsignif-
icant (P  0.74). However, the range of SHBG for women
(1–206 nmol/l) was nearly double that of men (1–109
nmol/l), albeit with considerable overlap. As a result,
although the effect on waist per absolute SHBG increment
was similar, the differences in waist between the highest
and lowest SHBG tertiles did differ signiﬁcantly by sex
(7.0  1.2 cm for men vs. 13.6  1.1 cm for women, P 
0.0001). Finally, when both WHR and SHBG were added to
the apoB ANCOVA model (Table 3), the sex-diabetes
interaction became marginally nonsigniﬁcant (P  0.053).
Ethnic heterogeneity. In each of the IRAS ethnic groups
(Hispanics, African Americans, and non-Hispanic whites),
the differences between diabetic and nondiabetic subjects
were higher in women than men for apoB and WHR and
lower for SHBG (data not shown).
DISCUSSION
Our objective was to understand why atherogenic risk
differs more between diabetic and nondiabetic women
than between diabetic and nondiabetic men. Our analysis
focused on differences in cardiovascular risk proﬁles to
assess whether they might explain, at least in part, the
alarmingly higher risk in diabetic women. In the IRAS
database, compared with nondiabetic women, diabetic
women have a more atherogenic lipoprotein proﬁle, a
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DIABETES, VOL. 57, DECEMBER 2008 3293higher systolic blood pressure, and a more proinﬂamma-
tory proﬁle. Although many of these differences exist
between diabetic and nondiabetic men, all are less pro-
nounced, some are nonsigniﬁcant, and one, LDL choles-
terol, was lower in diabetic than nondiabetic men. Of
importance, the key ﬁndings were consistent across the
three different ethnic groups in IRAS.
Our data indicate that sex is a critical determinant of
atherogenic lipoprotein levels in diabetes. As evidenced
both by apoB and LDL particle count, differences in
atherogenic particle number were much more pronounced
between diabetic and nondiabetic women than between
diabetic and nondiabetic men. It is important to note that
the differences in apoB and LDL particle count were more
pronounced than differences in LDL cholesterol or non-
HDL cholesterol. Our data extend earlier reports of sex-
related differences of apoB between diabetic and
nondiabetic subjects (17,18). Not only was the average
apoB highest in diabetic women, almost one-half of dia-
betic women had a markedly elevated apoB. ApoB was
signiﬁcantly higher in diabetic women than in diabetic
men. Our results also demonstrate that each class of apoB
lipoprotein particles—VLDL, IDL, and LDL—was signiﬁ-
cantly higher in diabetic women. The higher total LDL
particle number was principally due to more small dense
LDL, explaining why LDL cholesterol inadequately esti-
mated the differences in LDL. That the overall balance
of the atherogenic lipoproteins was substantially altered
in diabetic women is evident from the apoB–to–apoA-I
ratio.
These data are the most complete characterization of
the plasma lipoproteins in these groups to date. Our
ﬁndings concerning apoB plus the higher systolic blood
pressure and CRP go far to explain the markedly higher
risk of vascular disease in diabetic women. The differences
in apoB are particularly striking. Adjusting for apoB abol-
ished the signiﬁcance of the sex-diabetes interaction of
each of the other cardiovascular risk factors. Despite this
result, we believe a more complete explanation of the
sex–diabetes–cardiovascular risk interaction is likely mul-
tifactorial with apoB being a key factor. It is possible that
the greater cross-sectional diabetes-sex interaction of
apoB may be offset by the greater longitudinal association
of another measure with cardiovascular events. However,
this does not appear to be the case in Framingham and
INTERHEART reports (13,21) that have shown a greater
increase in risk per SD of apoB than of LDL cholesterol or
non-HDL cholesterol.
Given how clinically important the differences in apoB
appear to be, we have tried to uncover possible pathophys-
iological mechanisms. HyperTg/hyperapoB (22) was the
dominant atherogenic dyslipoproteinemia in the diabetic
women and is characterized by higher VLDL and LDL
particle numbers with predominantly small, dense LDL
due to increased secretion of apoB lipoprotein particles by
the liver (23,24). The mechanism of increased secretion of
FIG. 2. Waist and hip circumferences by BMI quintile for nondiabetic men (NM), diabetic men (DM), nondiabetic women (NW), and diabetic
women (DW). Both measures are indexed by dividing by the mean circumference for the lowest BMI quintile of nondiabetic subjects. For each
group, the slope for waist circumference differs signiﬁcantly from the slope for hip circumference (P < 0.001). Signiﬁcant differences in intercept
and slope (P < 0.05) are as follows. A: All intercepts set  1; waist slope, NW > NM. B: Waist intercept, DW 0.07 > DM. C: Waist intercept, DM
0.002 > NM; hip intercept, DM 0.06 < NM; hip slope, DM > NM. D: Waist intercept, DW 0.06 > NW; hip intercept, DM 0.10 < NM.
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ﬂux to the liver is one of the key components (25). In this
regard, the differences in body composition of the two
groups of women are striking, particularly because efﬂux
of fatty acids from adipose tissue is the major determinant
of fatty acid ﬂux to the liver (26).
The absolute differences in measures of body composi-
tion were greater between the two groups of women than
between the two groups of men. Not only were the
differences in body composition less marked between the
two groups of men, but abdominal obesity was already a
prominent feature in nondiabetic men. Moreover, at any
given BMI, the relative distribution of upper and lower
body adipose tissue was similar between diabetic and
nondiabetic men. By contrast, at any given BMI, waist
circumference was greater in diabetic women compared
with nondiabetic women, whereas hip circumference was
less. Thus, although there was little difference in regional
adipose tissue between the two groups of men, there were
clear differences in the degree of regional expansion
between the two groups of women.
Expansion of visceral and deep subcutaneous adipose
tissue compartments is associated with high transmembrane
adipocyte fatty ﬂuxes, which was evidenced in our study by
higher plasma FFA levels (26,27). Higher plasma FFA are
necessarily associated with increased hepatic fatty acid ﬂux
and therefore with increased hepatic apoB secretion (25,26).
All of our observations are therefore consistent with 1) the
smaller gap in apoB between the two groups of men, 2) the
higher apoB in both male groups than in nondiabetic women,
and 3) the greater apoB in diabetic women than in any of the
other groups. It therefore seems reasonable to suggest that
the atherogenic transformation of the lipoprotein proﬁle
within diabetic women was due to the marked expansion and
transformation of the distribution of adipose tissue. Differ-
ences in the distribution of body fat may also account for the
diabetes-related CRP difference that was selective for women
(28,29).
What then could explain the differences in adipose
tissue between diabetic and nondiabetic subjects, which
were particularly pronounced in women? We propose that
the cross-sectional data of this study be used to generate
prospective hypotheses for longitudinal testing. As adipo-
cytes form and mature, they accumulate and sequester
dietary triglycerides. Consequently, energy intake must
increase to meet essential metabolic demands. Multiple in
vitro studies have established that insulin is a potent
stimulant of adipogenesis (30–32), and plasma insulin has
been correlated with subsequent visceral obesity (33).
Elevated insulin levels could be a consequence of obesity,
but alternatively, based on our results, we query whether
sustained elevation of plasma insulin, as part of a complex
hormonal interaction, might play a role in producing an
expansion of abdominal adipose tissue, which is particu-
larly pronounced in diabetic women.
In summary, our data demonstrate that for multiple
variables, the difference in atherogenic proﬁle between
diabetic and nondiabetic women is more pronounced than
between diabetic and nondiabetic men. In this report, the
most striking differences involve elevations of plasma
apoB, C-reactive protein, and systolic blood pressure.
Because these are modiﬁable risk factors, our observa-
tions point to the potential to ameliorate the loss of
cardiovascular protection in diabetic women.
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